beta

ALBO

Albireo Pharma Inc.

Albo

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-13-2018 08-07-2018 05-17-2018 03-15-2018 11-14-2017 08-21-2017 05-10-2017
Actual EPS -1.17 -1.22 -0.15 -0.55 -0.73 -0.86 -1.06
Consensus EPS -0.97 -0.98 3.75 -0.78 -0.85 -0.83 -0.91
Estimated EPS -0.97 -0.98 3.75 -0.78 -0.85 -0.83 -0.91
Number of Estimates 5 5 3 4 3 2 1
EPS Surprise -$0.20 -$0.24 -$3.90 $0.23 $0.12 -$0.03 -$0.15

Stats

Summary

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of the drug reformulation technology. The company is engaged in the development an oral insulin to treat diabetes.

Market Cap: 303 Million

Primary Exchange: NASDAQ Capital Market

Website: http://www.albireopharma.com

Shares Outstanding: 8.9 Million

Float: 5.03 Million

Dividend: 0.0 (0.0%)

Beta: 1.629453

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 31.6 Thousand

Ethical Flags

Animal testing

Longest drawdown: 1340 trading days

From: 2013-08-02 To: 2018-12-07

Lowest Point:

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-13 14:25:06:000

Start Time: 08:30 End Time: 09:13 Albireo Pharma, Inc. (ALBO) Q3 2018 Earnings Conference Call November 13, 2018, 08:30 AM ET Executives Ron Cooper - President and CEO Simon Harford - CFO Patrick Horn - CMO Paul Arndt - IR, LifeSci Advisors Analysts Eun Yang - Jefferi… read more...

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-13 14:25:06:000

Start Time: 08:30 End Time: 09:13 Albireo Pharma, Inc. (ALBO) Q3 2018 Earnings Conference Call November 13, 2018, 08:30 AM ET Executives Ron Cooper - President and CEO Simon Harford - CFO Patrick Horn - CMO Paul Arndt - IR, LifeSci Advisors Analysts Eun Yang - Jefferi… read more...

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-13 14:25:06:000

Start Time: 08:30 End Time: 09:13 Albireo Pharma, Inc. (ALBO) Q3 2018 Earnings Conference Call November 13, 2018, 08:30 AM ET Executives Ron Cooper - President and CEO Simon Harford - CFO Patrick Horn - CMO Paul Arndt - IR, LifeSci Advisors Analysts Eun Yang - Jefferi… read more...

Albireo Pharma net loss widens in Q3

via: SeekingAlpha at 2018-11-13 09:21:16:000

Albireo Pharma ( ALBO ) Q3 results : Revenues: $0.2M. More news on: Albireo Pharma, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Albireo Pharma net loss widens in Q3

via: SeekingAlpha at 2018-11-13 09:21:16:000

Albireo Pharma ( ALBO ) Q3 results : Revenues: $0.2M. More news on: Albireo Pharma, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Albireo Pharma net loss widens in Q3

via: SeekingAlpha at 2018-11-13 09:21:16:000

Albireo Pharma ( ALBO ) Q3 results : Revenues: $0.2M. More news on: Albireo Pharma, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Albireo Pharma misses by $0.28, misses on revenue

via: SeekingAlpha at 2018-11-13 07:05:29:000

Albireo Pharma (NASDAQ: ALBO ): Q3 GAAP EPS of -$1.17 misses by $0.28 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Albireo Pharma misses by $0.28, misses on revenue

via: SeekingAlpha at 2018-11-13 07:05:29:000

Albireo Pharma (NASDAQ: ALBO ): Q3 GAAP EPS of -$1.17 misses by $0.28 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Albireo Pharma misses by $0.28, misses on revenue

via: SeekingAlpha at 2018-11-13 07:05:29:000

Albireo Pharma (NASDAQ: ALBO ): Q3 GAAP EPS of -$1.17 misses by $0.28 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Genfit And PBC: Is Elafibranor A Contender?

via: SeekingAlpha at 2018-10-10 18:21:52:000

Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Investment Thesis Genfit (GNFTF) is a small cap ($686M) French clinical stage biopharmaceutical company focused on the early diagnosis and preventive treatment of cardiometabolic disorders of high un… read more...

Genfit And PBC: Is Elafibranor A Contender?

via: SeekingAlpha at 2018-10-10 18:21:52:000

Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Investment Thesis Genfit (GNFTF) is a small cap ($686M) French clinical stage biopharmaceutical company focused on the early diagnosis and preventive treatment of cardiometabolic disorders of high un… read more...

Genfit And PBC: Is Elafibranor A Contender?

via: SeekingAlpha at 2018-10-10 18:21:52:000

Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Investment Thesis Genfit (GNFTF) is a small cap ($686M) French clinical stage biopharmaceutical company focused on the early diagnosis and preventive treatment of cardiometabolic disorders of high un… read more...

Albireo appoints Simon Harford as CFO

via: SeekingAlpha at 2018-10-10 08:58:16:000

Albireo Pharma (NASDAQ: ALBO ) appoints Simon Harford as Chief Financial Officer (CFO). Harford will succeed Tom Shea, who is stepping down from the role. More news on: Albireo Pharma, Inc., Healthcare stocks news, Read more … read more...

Albireo appoints Simon Harford as CFO

via: SeekingAlpha at 2018-10-10 08:58:16:000

Albireo Pharma (NASDAQ: ALBO ) appoints Simon Harford as Chief Financial Officer (CFO). Harford will succeed Tom Shea, who is stepping down from the role. More news on: Albireo Pharma, Inc., Healthcare stocks news, Read more … read more...

Albireo appoints Simon Harford as CFO

via: SeekingAlpha at 2018-10-10 08:58:16:000

Albireo Pharma (NASDAQ: ALBO ) appoints Simon Harford as Chief Financial Officer (CFO). Harford will succeed Tom Shea, who is stepping down from the role. More news on: Albireo Pharma, Inc., Healthcare stocks news, Read more … read more...

Albireo Pharma (ALBO) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-08-15 13:37:41:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Albireo Pharma (ALBO) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-08-15 13:37:41:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Albireo Pharma (ALBO) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-08-15 13:37:41:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-07 11:38:04:000

Albireo Pharma, Inc. (ALBO) Q2 2018 Earnings Conference Call August 7, 2018 8:30 a.m. ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Jan Mattsson - COO and Co-Founder Analysts Eun Yang - Jefferies Katherine Xu - William Bla… read more...

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-07 11:38:04:000

Albireo Pharma, Inc. (ALBO) Q2 2018 Earnings Conference Call August 7, 2018 8:30 a.m. ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Jan Mattsson - COO and Co-Founder Analysts Eun Yang - Jefferies Katherine Xu - William Bla… read more...

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-07 11:38:04:000

Albireo Pharma, Inc. (ALBO) Q2 2018 Earnings Conference Call August 7, 2018 8:30 a.m. ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Jan Mattsson - COO and Co-Founder Analysts Eun Yang - Jefferies Katherine Xu - William Bla… read more...

Albireo Pharma misses by $0.27, beats on revenue

via: SeekingAlpha at 2018-08-07 07:36:21:000

Albireo Pharma (NASDAQ: ALBO ): Q2 EPS of -$1.22 misses by $0.27 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Albireo Pharma misses by $0.27, beats on revenue

via: SeekingAlpha at 2018-08-07 07:36:21:000

Albireo Pharma (NASDAQ: ALBO ): Q2 EPS of -$1.22 misses by $0.27 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Albireo Pharma misses by $0.27, beats on revenue

via: SeekingAlpha at 2018-08-07 07:36:21:000

Albireo Pharma (NASDAQ: ALBO ): Q2 EPS of -$1.22 misses by $0.27 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Albireo And A4250: The Pediatric Remedy Making Waves

via: SeekingAlpha at 2018-07-30 07:33:00:000

Investment Thesis A4250, the lead drug candidate and an FDA rare pediatric disease designate from Albireo Pharma, is an investigative inhibitor of Ilea bile acid transporter (IBAT) that is being evaluated clinically for therapeutic efficacy in the pediatric cholestatic liver … read more...

Albireo And A4250: The Pediatric Remedy Making Waves

via: SeekingAlpha at 2018-07-30 07:33:00:000

Investment Thesis A4250, the lead drug candidate and an FDA rare pediatric disease designate from Albireo Pharma, is an investigative inhibitor of Ilea bile acid transporter (IBAT) that is being evaluated clinically for therapeutic efficacy in the pediatric cholestatic liver … read more...

Albireo And A4250: The Pediatric Remedy Making Waves

via: SeekingAlpha at 2018-07-30 07:33:00:000

Investment Thesis A4250, the lead drug candidate and an FDA rare pediatric disease designate from Albireo Pharma, is an investigative inhibitor of Ilea bile acid transporter (IBAT) that is being evaluated clinically for therapeutic efficacy in the pediatric cholestatic liver … read more...

Albireo Pharma nabs Rare Pediatric Disease tag for A4250 for rare liver disorder; shares up 7% premarket

via: SeekingAlpha at 2018-06-12 09:06:18:000

Thinly traded micro cap Albireo Pharma (NASDAQ: ALBO ) is up 7% premarket on light volume on the heels of its announcement that the FDA has granted Rare Pediatric Disease Designation for lead drug A4250 for the treatment of a rare life-threatening liver disease called progressi… read more...

Albireo Pharma nabs Rare Pediatric Disease tag for A4250 for rare liver disorder; shares up 7% premarket

via: SeekingAlpha at 2018-06-12 09:06:18:000

Thinly traded micro cap Albireo Pharma (NASDAQ: ALBO ) is up 7% premarket on light volume on the heels of its announcement that the FDA has granted Rare Pediatric Disease Designation for lead drug A4250 for the treatment of a rare life-threatening liver disease called progressi… read more...

Albireo Pharma nabs Rare Pediatric Disease tag for A4250 for rare liver disorder; shares up 7% premarket

via: SeekingAlpha at 2018-06-12 09:06:18:000

Thinly traded micro cap Albireo Pharma (NASDAQ: ALBO ) is up 7% premarket on light volume on the heels of its announcement that the FDA has granted Rare Pediatric Disease Designation for lead drug A4250 for the treatment of a rare life-threatening liver disease called progressi… read more...

Albireo Pharma's (ALBO) CEO Ron Cooper on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-17 12:13:04:000

Albireo Pharma, Inc. (ALBO) Q1 2018 Earnings Conference Call May 17, 2018 08:30 A.M. ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Paresh Soni - Chief Medical Officer Analysts Ritu Baral - Cowen and Company Unidentified An… read more...

Albireo Pharma EPS of -$0.15

via: SeekingAlpha at 2018-05-17 07:36:29:000

Albireo Pharma (NASDAQ: ALBO ): Q1 EPS of -$0.15 may not be comparable to consensus of $1.77. More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Biotech Forum: The Week Ahead

via: SeekingAlpha at 2018-04-09 10:38:18:000

It has always seemed that a fear of judgment is the mark of guilt and the burden of insecurity. Criss Jami, Killosophy Markets plunged Friday in reaction to escalating trade tensions between the U.S. and China. The major indices ended up again in the red last week. The… read more...

Biotech Forum: The Week Ahead

via: SeekingAlpha at 2018-04-09 10:38:18:000

It has always seemed that a fear of judgment is the mark of guilt and the burden of insecurity. Criss Jami, Killosophy Markets plunged Friday in reaction to escalating trade tensions between the U.S. and China. The major indices ended up again in the red last week. The… read more...

Albireo Pharma (ALBO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-29 13:43:51:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Albireo Pharma (ALBO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-29 13:43:51:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Albireo Pharma's (ALBO) CEO Ron Cooper on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-15 15:44:05:000

Albireo Pharma, Inc. (ALBO) Q4 2017 Results Earnings Conference Call March 15, 2018 08:30 AM ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Paresh Soni - Chief Medical Officer Analysts Liana Moussatos - Wedbush Securities K… read more...

Albireo Pharma's (ALBO) CEO Ron Cooper on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-15 15:44:05:000

Albireo Pharma, Inc. (ALBO) Q4 2017 Results Earnings Conference Call March 15, 2018 08:30 AM ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Paresh Soni - Chief Medical Officer Analysts Liana Moussatos - Wedbush Securities K… read more...

Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC

via: SeekingAlpha at 2018-01-26 19:57:23:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC

via: SeekingAlpha at 2018-01-26 19:57:23:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC

via: SeekingAlpha at 2018-01-26 19:57:23:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC

via: SeekingAlpha at 2018-01-26 19:57:23:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC

via: SeekingAlpha at 2018-01-26 19:57:23:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 1/25/18: OPK, ALBO, BMRA, ICBK, PGLC

via: SeekingAlpha at 2018-01-26 19:57:23:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Albireo to receive more than $55M on elobixibat approval in Japan

via: SeekingAlpha at 2018-01-19 08:24:58:000

Albireo Pharma (NASDAQ: ALBO ) announces that JapansMinistry of Health, Labor and Welfare has approved the new drug application for IBAT inhibitor elobixibat for the treatment of chronic constipation inJapan. More news on: Albireo Pharma, Inc., Healthcare … read more...

Your Daily Pharma Scoop: Gilead's Potential, Celgene CAR-T Candidate, Cellectar Soars

via: SeekingAlpha at 2017-12-07 08:00:00:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day ea… read more...

Albireo Pharma: Updates To Thesis

via: SeekingAlpha at 2017-11-17 15:39:29:000

Shares of Albireo Pharma ( ALBO ) have risen by close to 20% since I noted that this big pharma spinoff was fully funded with several catalysts lined up. ALBO data by YCharts Keys to the original bullish thesis included the following: Lead clinical candidate A4250, a selective inhibi… read more...

Albireo Pharma (ALBO) Presents At Jefferies 2017 London Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-17 13:28:18:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Planned equity offering roundup - healthcare

via: SeekingAlpha at 2017-11-16 16:45:32:000

Recent SEC filings for planned equity offerings: More news on: Bio-Path Holdings, Inc., Albireo Pharma, Inc., Mateon Therapeutics, Inc., Healthcare stocks news, Read more … read more...

Albireo Pharma (ALBO) Updates On Rare Cholestatic Diseases In Children (PFIC & Pruritus, IBAT Inhibition) - Slideshow

via: SeekingAlpha at 2017-10-27 14:30:32:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Albireo's A4250 shows treatment effect in mid-stage liver disease study

via: SeekingAlpha at 2017-10-20 09:33:31:000

Results from an open-label, dose-finding Phase 2 clinical trial assessing Albireo Pharma's ( ALBO ) lead candidate A4250 in children with cholestatic liver disease showed a treatment effect and favorable tolerability profile. The data will be presented at the Liver Meeting in Washington, … read more...

Midday Gainers / Losers

via: SeekingAlpha at 2017-10-13 12:45:09:000

Gainers: LBIX +153% . NETE +43% . CDTI +32% . MARK +22% . SOHU +14% . FRSX +14% . SPAR +13% . ALBO +12% . PN +11% . ZN +10% . More news on: Leading Brands Inc, Net Element International, Inc., Clean Diesel Technologies, Inc., Stocks on the move, Read mo… read more...

Albireo Pharma (ALBO) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-09-28 13:29:52:000

The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2016-11-04 30.0 1.0 30.0
Data provided for free by IEX